Table 6 Comparison of confounding factors among genotypes
Wild type | Heterozygotes mutant type | Homozygotes mutant type | P | |
|---|---|---|---|---|
ABCB1 rs1045642 (A > G) | 15 | 50 | 30 | |
Age | 65.9 ± 13.2 | 66.8 ± 11.3 | 64.1 ± 14.2 | 0.641 |
Weight | 65.4 ± 15.1 | 67.1 ± 10.9 | 70.4 ± 12.9 | 0.369 |
Amiodarone | 3 (20%) | 12 (24%) | 6 (20%) | 0.943 |
CrCl | 75.5 ± 25.1 | 73.6 ± 23.6 | 85.4 ± 20.6 | 0.120 |
CHA2DS2-VASc | 2.7 ± 2.0 | 2.6 ± 2.0 | 2.2 ± 1.8 | 0.555 |
HAS-BLED | 1.6 ± 1.0 | 1.5 ± 1.1 | 1.2 ± 1.0 | 0.342 |
ABCB1 rs1128503 (A > G) | 35 | 50 | 10 | |
Age | 66.6 ± 13.9 | 65.0 ± 11.4 | 67.3 ± 13.7 | 0.773 |
Weight | 65.4 ± 12.8 | 70.4 ± 11.7 | 62.1 ± 10.4 | 0.063 |
Amiodarone | 9 (25.7%) | 9 (18.0%) | 3 (30%) | 0.515 |
CrCl | 75.9 ± 24.4 | 78.0 ± 24.1 | 78.5 ± 16.4 | 0.914 |
CHA2DS2-VASc | 2.8 ± 2.2 | 2.3 ± 1.7 | 2.5 ± 1.9 | 0.517 |
HAS-BLED | 1.5 ± 1.1 | 1.4 ± 1.0 | 1.4 ± 1.1 | 0.983 |
ABCB1 rs4148738 (C > T) | 15 | 51 | 29 | |
Age | 67.3 ± 13.5 | 66.7 ± 12.0 | 63.5 ± 12.9 | 0.479 |
Weight | 65.1 ± 14.5 | 67.2 ± 11.8 | 70.3 ± 11.7 | 0.382 |
Amiodarone | 1 (6.7%) | 15 (29.4%) | 5 (17.2%) | 0.147 |
CrCl | 71.3 ± 25.4 | 74.2 ± 23.2 | 86.7 ± 20.3 | 0.052 |
CHA2DS2-VASc | 3.1 ± 2.0 | 2.5 ± 2.0 | 2.5 ± 1.9 | 0.349 |
HAS-BLED | 1.7 ± 1.2 | 1.5 ± 1.0 | 1.1 ± 1.0 | 0.155 |
ABCB1 rs4728709 (G > A) | 66 | 23 | 2 | |
Age | 65.6 ± 13.2 | 65.3 ± 11.5 | 66.0 ± 11.4 | 0.988 |
Weight | 68.1 ± 12.5 | 70.3 ± 10.9 | 57.5 ± 3.5 | 0.344 |
Amiodarone | 17 (25.8%) | 3 (13.0%) | 1 (50%) | 0.324 |
CrCl | 76.2 ± 23.5 | 84.8 ± 21.4 | 65.8 ± 10.5 | 0.253 |
CHA2DS2-VASc | 2.7 ± 2.1 | 1.8 ± 1.6 | 2.5 ± 0.7 | 0.157 |
HAS-BLED | 1.5 ± 1.1 | 1.0 ± 0.9 | 2 ± 0 | 0.096 |
CYP3A4 rs2242480(C > T) | 39 | 45 | 7 | |
Age | 61.4 ± 11.8 | 64.5 ± 12.7 | 67.9 ± 12.5 | 0.301 |
Weight | 65.4 ± 12.4 | 69.9 ± 13.5 | 67.2 ± 10.2 | 0.476 |
Amiodarone | 9 (23.1%) | 10 (22.2%) | 2 (28.6%) | 0.932 |
CrCl | 80.0 ± 21.0 | 80.5 ± 21.0 | 75.2 ± 25.6 | 0.588 |
CHA2DS2-VASc | 1.6 ± 1.0 | 2.2 ± 1.8 | 2.9 ± 2.1 | 0.133 |
HAS-BLED | 1.1 ± 1.1 | 1.3 ± 1.1 | 1.5 ± 1.1 | 0.506 |
CYP3A4 rs4646437(G > A) | 60 | 28 | 3 | |
Age | 66.0 ± 12.5 | 66.0 ± 13.0 | 56.0 ± 9.8 | 0.403 |
Weight | 68.2 ± 11.1 | 69.0 ± 14.3 | 66.0 ± 12.3 | 0.911 |
Amiodarone | 11 (18.3%) | 9 (32.1%) | 1(33.3%) | 0.135 |
CrCl | 77.8 ± 24.6 | 78.1 ± 19.8 | 85.3 ± 26.9 | 0.863 |
CHA2DS2-VASc | 2.5 ± 2.1 | 2.4 ± 1.8 | 2.0 ± 1.0 | 0.908 |
HAS-BLED | 1.4 ± 1.1 | 1.5 ± 1.1 | 1.4 ± 0 | 0.699 |
CYP3A5 rs776746 (T > C) | 7 | 40 | 41 | |
Age | 67.1 ± 12.2 | 65.3 ± 13.9 | 66.8 ± 11.4 | 0.848 |
Weight | 64.4 ± 11.3 | 70.8 ± 13.6 | 66.4 ± 10.3 | 0.182 |
Amiodarone | 1 (14.3%) | 7 (17.5%) | 12 (29.3%) | 0.502 |
CrCl | 73.6 ± 14.8 | 77.8 ± 20.2 | 77.1 ± 25.7 | 0.908 |
CHA2DS2-VASc | 2.0 ± 1.3 | 2.3 ± 1.8 | 2.8 ± 2.2 | 0.352 |
HAS-BLED | 1.3 ± 1.1 | 1.4 ± 1.1 | 1.4 ± 1.0 | 0.932 |
ABCG2 rs2231137(C > T) | 42 | 41 | 8 | |
Age | 65.9 ± 12.8 | 65.5 ± 12.5 | 65.5 ± 13.9 | 0.990 |
Weight | 68.0 ± 11.4 | 68.9 ± 13.4 | 67.9 ± 8.6 | 0.940 |
Amiodarone | 15 (35.7%) | 4(9.8%) | 2 (25.0%) | 0.012* |
CrCl | 77.8 ± 21.0 | 76.7 ± 25.2 | 89.4 ± 22.0 | 0.459 |
CHA2DS2-VASc | 2.0 ± 1.9 | 2.8 ± 2.0 | 2.8 ± 1.7 | 0.176 |
HAS-BLED | 1.3 ± 1.2 | 1.5 ± 1.0 | 1.4 ± 0.7 | 0.750 |
ABCG2 rs2231142(G > T) | 45 | 37 | 9 | |
Age | 66.5 ± 13.1 | 64.0 ± 11.6 | 68.4 ± 14.8 | 0.534 |
Weight | 66.9 ± 11.5 | 70.2 ± 13.2 | 68.0 ± 9.5 | 0.486 |
Amiodarone | 8 (17.8%) | 10(27.0%) | 3 (33.3%) | 0.411 |
CrCl | 79.2 ± 21.8 | 78.3 ± 25.6 | 72.6 ± 17.3 | 0.763 |
CHA2DS2-VASc | 2.6 ± 2.0 | 2.3 ± 1.9 | 2.4 ± 1.9 | 0.726 |
HAS-BLED | 1.4 ± 0.9 | 1.4 ± 1.2 | 1.6 ± 1.1 | 0.876 |